After setbacks, cema-cel might have a path to approval in lymphoma.
ApexOnco Front Page
Recent articles
Optimum-02 virtually replicates phase 1, and a filing will follow.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
Circle Pharma and Verismo feature in coveted sessions.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
